ARTICLE

ALOPECIA REVIEW OF EPIDEMIOLOGY PATHOGENESIS AND NOVEL TREATMENT STRATEGIES

  1. HOME
  2. ARTICLE

03 Pages : 20-27

http://dx.doi.org/10.31703/gpsr.2019(IV-I).03      10.31703/gpsr.2019(IV-I).03      Published : Dec 2019

Alopecia: Review of Epidemiology, Pathogenesis, and Novel Treatment Strategies

Abstract

    Alopecia is an autoimmune and non-communicable disorder. The immune system, especially Tlymphocytes, present around the hair follicle attacks, cause inflammation and loss of hair from some or all areas of the scalp. It is highly prevalent in the United States; an estimated 4.5 million are affected by this disease. Finasteride and minoxidil are mostly used to treat alopecia in the form of solutions and gels. However, their use has been limited due to severe adverse effects observed during therapy. This article summarizes the epidemiology, risk factors, pathophysiology, sign and symptoms, and diagnostic parameters with a focus on novel treatment strategies.

    Alopecia, Hair Loss, Etiology, Pathogenesis, Diagnostic Parameters

    (1) Sobia Noreen
    Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan.
    (2) Fahad Pervaiz
    Associate Professor, Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan.
    (3) Irsah Maqbool
    Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan.
    (4) Madiha Saleem
    Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan.
Fulltext PDF

References

  • Aghaei, S. (2008). An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian Journal of Dermatology, Venereology, and Leprology, 74(6), 611.
  • Aghaei, A., Alsantali, A., Wang, E., McElwee, K. J., & Shapiro, J. (2010). Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. Journal of the American Academy of Dermatology, 62(2), 177-188.
  • Batalla, A., Flórez, Á., Abalde, T., & Vázquez-Veiga, H. (2016). Methotrexate in alopecia areata: A report of three cases. International journal of trichology, 8(4), 188.
  • Bhat, Y., Sajad, P., & Hassan, I. (2014). Etiopathogenesis of alopecia areata. Hair Ther Transplant, 4(1000124), 2167-0951.1000125.
  • Cotsarelis, G., Sun, T.-T., & Lavker, R. M. (1990). Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell, 61(7), 1329-1337.
  • Darwin, E., Hirt, P. A., Fertig, R., Doliner, B., Delcanto, G., & Jimenez, J. J. (2018). Alopecia areata: Review of epidemiology, clinical features, pathogenesis, and new treatment options. International journal of trichology, 10(2), 51.
  • El Taieb, M. A., Ibrahim, H., Nada, E. A., & Seif Al-Din, M. (2017). Platelets rich plasma versus minoxidil 5 Percent in treatment of alopecia areata: a trichoscopic evaluation. Dermatologic therapy, 30(1), e12437.
  • Ellis, J. A., Sinclair, R., & Harrap, S. B. (2002). Androgenetic alopecia: pathogenesis and potential for therapy. Expert reviews in molecular medicine, 2(1), 1-11.
  • Farshi, S., Mansouri, P., Safar, F., & Khiabanloo, S. R. (2010). Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? A pilot study. International journal of dermatology, 49(10), 1188-1193.
  • Fricke, A. C. V., & Miteva, M. (2015). Epidemiology and burden of alopecia areata: a systematic review. Clinical, Cosmetic and Investigational Dermatology, 8, 397.
  • Gilhar, A., Etzioni, A., & Paus, R. (2012). Alopecia areata. New England Journal of Medicine, 366(16), 1515-1525.
  • Hammerschmidt, M., & Mulinari Brenner, F. (2014). Efficacy and safety of methotrexate in alopecia areata. Anais brasileiros de dermatologia, 89(5), 729-734.
  • Jiménez, F., & Poblet, E. (2013). Is hair transplantation indicated in frontal fibrosing alopecia? The results of test grafting in three patients. Dermatologic Surgery, 39(7), 1115- 1118.
  • Johnstone, M. A., & Albert, D. M. (2002). Prostaglandin-induced hair growth. Survey of ophthalmology, 47, S185-S202.
  • Kar, B. R., Handa, S., Dogra, S., & Kumar, B. (2005). Placebo-controlled oral pulse prednisolone therapy in alopecia areata. Journal of the American Academy of Dermatology, 52(2), 287-290.
  • Kim, B. J., Uk min, S., Park, K. Y., Choi, J. W., Park, S. W., Youn, S. W., . . . Huh, C. H. (2008). Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. Journal of Dermatological Treatment, 19(4), 216-220.
  • Kretzschmar, K., Cottle, D. L., Schweiger, P. J., & Watt, F. M. (2015). The androgen receptor antagonizes Wnt/β-catenin signaling in epidermal stem cells. Journal of Investigative Dermatology, 135(11), 2753-2763.
  • Kumaresan, M. (2010). Intralesional steroids for alopecia areata. International journal of trichology, 2(1), 63.
  • Lee, H. H., Gwillim, E., Patel, K. R., Hua, T., Rastogi, S., Ibler, E., & Silverberg, J. I. (2020). Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 82(3), 675-682.
  • Madani, S., & Shapiro, J. (2000). Alopecia areata update. Journal of the American Academy of Dermatology, 42(4), 549-566.
  • Mirzoyev, S. A., Schrum, A. G., Davis, M. D., & Torgerson, R. R. (2014). Lifetime incidence risk of Alopecia Areata estimated at 2.1 percent by Rochester Epidemiology Project, 1990-2009. The Journal of investigative dermatology, 134(4), 1141.
  • Motofei, I. G., Rowland, D. L., Georgescu, S. R., Tampa, M., Baconi, D., Stefanescu, E., . . . Paunica, S. (2016). Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain. Journal of Dermatological Treatment, 27(6), 495-497.
  • Mubki, T., Rudnicka, L., Olszewska, M., & Shapiro, J. (2014a). Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination. Journal of the American Academy of Dermatology, 71(3), 415. e411-415. e415.
  • Mubki, T., Rudnicka, L., Olszewska, M., & Shapiro, J. (2014b). Evaluation and diagnosis of the hair loss patient: part II. Trichoscopic and laboratory evaluations. Journal of the American Academy of Dermatology, 71(3), 431. e431-431. e411.
  • Ohyama, M., Shimizu, A., Tanaka, K., & Amagai, M. (2010). Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata. Journal of dermatological science, 58(2), 154- 157.
  • Perera, E., Yip, L., & Sinclair, R. (2014). Alopecia areata. Hair Ther Transplant, 4(1), 118.
  • Pervaiz, F., Saleem, M., Ashames, A., Rehmani, S., Qaiser, R., Noreen, S., & Murtaza, G. (2020). Development and ex-vivo skin permeation studies of finasteride-poly (lactic acid-co- glycolic acid) and minoxidil-chitosan nanoparticulate systems. Journal of Bioactive and Compatible Polymers, 35(2), 77-91.
  • Prager, N., Bickett, K., French, N., & Marcovici, G. (2002). A randomized, double-blind, placebo- controlled trial to determine the effectiveness of botanically derived inhibitors of 5-α- reductase in the treatment of androgenetic alopecia. The Journal of Alternative & Complementary Medicine, 8(2), 143-152.
  • Price, V. H. (2003). Therapy of alopecia areata: on the cusp and in the future. Paper presented at the Journal of Investigative Dermatology Symposium Proceedings.
  • Rácz, E., Gho, C., Moorman, P., Noordhoek Hegt, V., & Neumann, H. (2013). Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review. Journal of the European Academy of Dermatology and Venereology, 27(12), 1461-1470.
  • Samrao, A., Chew, A. L., & Price, V. (2010). Frontal fibrosing alopecia: a clinical review of 36 patients. British Journal of Dermatology, 163(6), 1296-1300.
  • Sinclair, R. (2002). Androgenetic alopecia: pathogenesis and potential for therapy.
  • Singh, G., & Lavanya, M. (2010). Topical immunotherapy in alopecia areata. International journal of trichology, 2(1), 36.
  • Tang, L., Cao, L., Pelech, S., Lui, H., & Shapiro, J. (2003). Cytokines and Signal Transduction Pathways Mediated by Anthralin in Alopecia Areata-Affected Dundee ExperimentalBalding Rats. Paper presented at the Journal of Investigative Dermatology Symposium Proceedings.
  • Thornton, M., Taylor, A. H., Mulligan, K., Al-Azzawi, F., Lyon, C. C., O'Driscoll, J., & Messenger, A. G. (2003). The distribution of estrogen receptor β is distinct to that of estrogen receptor α and the androgen receptor in human skin and the pilosebaceous unit. Paper presented at the Journal of Investigative Dermatology Symposium Proceedings.
  • Van der Steen, P., & Happle, R. (1993). Topical immunotherapy of alopecia areata. Dermatologic clinics, 11(3), 619-622.
  • Wasserman, D., Guzman-Sanchez, D. A., Scott, K., & McMichael, A. (2007). Alopecia areata. International journal of dermatology, 46(2), 121-131.
  • Wu, S. Z., Wang, S., Ratnaparkhi, R., & Bergfeld, W. F. (2018). Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients. Pediatric Dermatology, 35(6), 817- 820.
  • Yip, L., & Sinclair, R. D. (2006). Antiandrogen therapy for androgenetic alopecia. Expert Review of Dermatology, 1(2), 261-269.
  • Zakaria, W., Passeron, T., Ostovari, N., Lacour, J.-P., & Ortonne, J.-P. (2004). 308-nm excimer laser therapy in alopecia areata. Journal of the American Academy of Dermatology, 51(5), 837-838.

Cite this article

APA

    APA : Noreen, S., Pervaiz, F., & Maqbool, I. (2019). Alopecia: Review of Epidemiology, Pathogenesis, and Novel Treatment Strategies. Global Pharmaceutical Sciences Review, IV(I), 20-27. https://doi.org/10.31703/gpsr.2019(IV-I).03

CHICAGO

    CHICAGO : Noreen, Sobia, Fahad Pervaiz, and Irsah Maqbool. 2019. "Alopecia: Review of Epidemiology, Pathogenesis, and Novel Treatment Strategies." Global Pharmaceutical Sciences Review, IV (I): 20-27 doi: 10.31703/gpsr.2019(IV-I).03

HARVARD

    HARVARD : NOREEN, S., PERVAIZ, F. & MAQBOOL, I. 2019. Alopecia: Review of Epidemiology, Pathogenesis, and Novel Treatment Strategies. Global Pharmaceutical Sciences Review, IV, 20-27.

MHRA

    MHRA : Noreen, Sobia, Fahad Pervaiz, and Irsah Maqbool. 2019. "Alopecia: Review of Epidemiology, Pathogenesis, and Novel Treatment Strategies." Global Pharmaceutical Sciences Review, IV: 20-27

MLA

    MLA : Noreen, Sobia, Fahad Pervaiz, and Irsah Maqbool. "Alopecia: Review of Epidemiology, Pathogenesis, and Novel Treatment Strategies." Global Pharmaceutical Sciences Review, IV.I (2019): 20-27 Print.

OXFORD

    OXFORD : Noreen, Sobia, Pervaiz, Fahad, and Maqbool, Irsah (2019), "Alopecia: Review of Epidemiology, Pathogenesis, and Novel Treatment Strategies", Global Pharmaceutical Sciences Review, IV (I), 20-27

TURABIAN

    TURABIAN : Noreen, Sobia, Fahad Pervaiz, and Irsah Maqbool. "Alopecia: Review of Epidemiology, Pathogenesis, and Novel Treatment Strategies." Global Pharmaceutical Sciences Review IV, no. I (2019): 20-27. https://doi.org/10.31703/gpsr.2019(IV-I).03